Lercanidipine Medreg (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels in arterial smooth muscle. This inhibition prevents calcium entry, causing the muscles to relax, leading to vasodilation and a reduction in peripheral resistance, which ultimately lowers blood pressure.

The appropriate dose of Lercanidipine Medreg is determined by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of lercanidipine in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lercanidipine belongs to the dihydropyridine calcium‑channel blocker class, which primarily causes arterial vasodilation. Compared with ACE inhibitors or beta‑blockers, it may have a lower incidence of cough but can cause peripheral edema more frequently. Choice of therapy depends on patient profile and comorbidities.

Lercanidipine Medreg tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Lercanidipine Medreg is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water and do not crush or chew it.

Serious adverse events, although rare, include severe hypotension, myocardial infarction, hepatic dysfunction, allergic reactions such as angioedema, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience symptoms like fainting, chest pain, severe rash, or swelling of the face or throat.

Lercanidipine Medreg is contraindicated in patients with known hypersensitivity to lercanidipine or any component of the formulation. Caution is advised in individuals with severe hepatic impairment, unstable angina, or those taking strong CYP3A4 inhibitors.